In this episode of The Biotech Capital Compass, Hartaj Singh breaks down the unique seasonality of biotech investing—and why now may be a pivotal setup for opportunity. While Q1 earnings tend to be the weakest for biopharma due to insurance resets, price caps, and inventory drawdowns, historical patterns show a shift starting in May. That’s when clinica…
Listen to this episode with a 7-day free trial
Subscribe to The Biotech Capital Compass to listen to this post and get 7 days of free access to the full post archives.
